Gedian Humanwell successfully passed the EDQM audit

In November 2023, Gedian Humanwell is subject to an official audit by the European Pharmacopoeia Commission (EDQM). After a professional and rigorous evaluation, our company's API -- cyproterone acetate, successfully passed the EU-GMP audit in April 2024.

In this audit, the professional team conducted a comprehensive and detailed review of the company's production process, quality management, facility management, material traceability and laboratory systems, etc. After rigorous evaluation, the product quality fully meets international standards and is officially recognized.

This milestone achievement not only highlights Gedian Humanwell's outstanding performance in the quality of drug production, but also proves its determination and ability to meet international standards. With the continuous strengthening of GMP on-site inspection by the EU, this audit undoubtedly provides a solid guarantee for the company to further expand the European and global markets.

Gedian Humanwell will continue to be committed to drug research and development and quality improvement, deepen trust and cooperation with customers, and reward global users with excellent products and services.